Home » Stocks » ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited (ASLN)

Stock Price: $1.71 USD -0.13 (-7.07%)
Updated Oct 26, 2020 1:04 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 64.96M
Revenue (ttm) 3.00M
Net Income (ttm) -47.07M
Shares Out 37.99M
EPS (ttm) -1.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $1.71
Previous Close $1.84
Change ($) -0.13
Change (%) -7.07%
Day's Open 1.85
Day's Range 1.70 - 1.85
Day's Volume 35,877
52-Week Range 0.35 - 8.18

More Stats

Market Cap 64.96M
Enterprise Value 61.41M
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 37.99M
Float 36.30M
EPS (basic) -0.29
EPS (diluted) -1.24
FCF / Share -0.16
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 239,908
Short Ratio 2.97
Short % of Float 0.66%
Beta 2.71
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 21.65
PB Ratio 6.05
Revenue 3.00M
Operating Income -45.58M
Net Income -47.07M
Free Cash Flow -25.51M
Net Cash 3.55M
Net Cash / Share 0.09
Gross Margin 57,884.51%
Operating Margin -1,519.30%
Profit Margin -1,568.90%
FCF Margin -850.21%
ROA -41.56%
ROE -769.78%
ROIC -430.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(221.64% upside)
Current: $1.71
Target: 5.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit2.59--11.42
Operating Income-45.58-42.35-39.14-8.70
Net Income-47.07-42.19-39.89-9.05
Shares Outstanding160168168-
Earnings Per Share-0.29-0.28-0.32-0.09
Operating Cash Flow-25.51-39.72-34.48-5.80
Capital Expenditures--23.08-0.30-0.46
Free Cash Flow-25.51-62.81-34.78-6.25
Cash & Equivalents22.2028.9150.5751.74
Total Debt18.6513.979.688.34
Net Cash / Debt3.5514.9340.8943.40
Book Value-1.6830.6235.5141.57
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ASLAN Pharmaceuticals Limited
Country Singapore
CEO Carl Aslan Jason Morton Firth

Stock Information

Ticker Symbol ASLN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ASLN
IPO Date May 4, 2018


ASLAN Pharmaceuticals Limited, a clinical-stage immunology and oncology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and a small molecule inhibitor targeting oncology. Its partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.